Zalicus Inc Com (NASDAQ:ZLCS)

CAPS Rating: 4 out of 5

A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.

Recs

0
Player Avatar slycat910 (59.96) Submitted: 8/16/2012 5:37:35 PM : Outperform Start Price: $1.38 ZLCS Score: -75.90

Nobody likes pain.

Featured Broker Partners


Advertisement